Elexacaftor/tezacaftor/ivacaftor treatment is associated with epigenetic age deceleration in cystic fibrosis
This pilot longitudinal study demonstrates that initiating elexacaftor/tezacaftor/ivacaftor (ETI) treatment in cystic fibrosis patients significantly decelerates epigenetic aging, an effect that correlates with reduced inflammatory biomarkers and improved clinical disease markers.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Every living thing carries a biological clock that ticks away inside its cells, distinct from the calendar on the wall. While we all age as time passes, the speed at which our bodies wear down can vary. Some people seem to age faster than their years suggest, their cells showing signs of wear and tear that belong to someone much older. Scientists have developed ways to measure this "biological age" by looking at chemical tags on our DNA, which act like a record of how our cells have been treated by life, disease, and inflammation. In conditions where the body is constantly fighting itself, such as cystic fibrosis, researchers suspect this internal clock might be running too fast, driven by the relentless fire of chronic inflammation. The question remains whether fixing the root cause of the disease can actually slow this clock down, allowing the body's biology to catch up with the person's actual years.
A new study set out to see if a powerful new treatment could do just that for people with cystic fibrosis. This condition is a genetic disorder that causes thick mucus to build up in the lungs and other organs, leading to severe, long-term inflammation. For years, patients lived with this constant internal battle, which many experts believed accelerated their aging process. Recently, a triple-drug therapy known as elexacaftor/tezacaftor/ivacaftor, or ETI, has transformed care for many patients by restoring the function of the defective protein that causes the disease. While doctors knew this treatment improved lung function and reduced symptoms, they did not know if it could reverse the deeper, cellular signs of aging. To find out, a team of researchers tracked a small group of eight adults with cystic fibrosis who had never taken this type of medication before. They collected blood samples from these individuals right before they started the treatment and again one year later, looking closely at the chemical marks on their DNA to see how their biological age had changed.
The results revealed a striking shift in the body's internal timeline. Before the treatment began, the participants' cells showed signs of aging that were, on average, nearly two years older than their actual chronological age. This suggested their bodies were indeed aging faster than normal, likely due to the stress of their disease. However, after one year on the new medication, the picture changed dramatically. The biological age of their cells dropped, shifting to a point where their cells appeared nearly two years younger than their actual age. This was not a small fluctuation; it was a significant reversal, suggesting that the treatment did more than just clear mucus from the lungs—it appeared to reset the pace of cellular aging. The researchers found that this slowing of the aging clock was closely tied to the body's level of inflammation. When the participants had higher levels of specific inflammatory markers in their blood, their cells appeared older. As the treatment reduced these inflammatory signals, the biological age of their cells decreased in step.
The study also connected these cellular changes to the physical health of the patients. Those who saw the biggest improvements in their lung function, measured by how much air they could force out of their lungs, also showed the greatest reduction in biological age. Conversely, those who still had higher levels of salt in their sweat—a key indicator of how well the disease was controlled—had cells that remained biologically older. This link suggests that the treatment works by calming the chronic inflammation that drives the aging process, allowing the body to heal at a cellular level. The researchers noted that this change happened quickly, within just one year, which is a short time in the grand scheme of human aging.
While these findings are promising, the researchers are careful to note that this was a small pilot study involving only eight people. Because the group was so small, they could not prove that the treatment was the sole cause of the change, nor could they rule out other factors that might have influenced the results. The study suggests a strong connection between the treatment, reduced inflammation, and a slower biological aging process, but it does not yet confirm that this effect will last a lifetime or that it will prevent future complications. The authors emphasize that larger studies are needed to confirm these early results. Nevertheless, the observation that a drug can alter the body's biological age in such a short time offers a new perspective on how treating the root cause of a disease might do more than just manage symptoms. It hints that by stopping the fire of inflammation, we might be able to help the body's internal clock tick at a more natural, healthier pace.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.